SEOUL-SEMICONDUCTOR
24.5.2017 09:09:07 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) — On April 28, 2017, Seoul Semiconductor Europe GmbH (“Seoul”) filed a patent infringement claim in Germany at the District Court of Düsseldorf against Mouser Electronic Inc. (“Mouser), a global electronic components distributor, which it accused of selling Everlight LED products.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170524005266/en/
In its complaint, Seoul asserted that Everlight’s Mid-Power LED products are infringing Seoul’s patent rights. Seoul has sought a permanent injunction, damages, and recall and destruction of the allegedly infringing products.
The asserted patent serves to improve the light extraction performance of LED devices by enhancing internal-reflection efficiency, which has been widely used in mid-power and high-power LEDs.
This patent litigation is the second patent infringement litigation by Seoul or its affiliate affecting Everlight’s LED products. In March 2017, Seoul Semiconductor Co., Ltd. filed a patent infringement claim in Germany, accusing high-power LED products manufactured by Everlight as well as other LED manufacturers. These patent litigations underscore Seoul’s commitment to protecting its intellectual property rights against infringement, including products consisting of mid-power LEDs and high-power LEDs.
In addition to Seoul’s patent infringement actions, Everlight has been implicated in other patent infringement lawsuits as described below. Nam Ki-bum, Vice President of the Research Center at Seoul, said, “Several LED companies have grown rapidly in a short period of time despite a lack of valuable patent portfolios, which is like building a castle on quicksand. There is no underlying foundation for the company’s products. Seoul, however, has been investing 10% of its revenue in research and development for many years to develop innovative technology and strengthen our patent portfolio. To support a fair market that respects intellectual property rights, Seoul will continuously monitor and take action against alleged infringers in any countries where infringement occurs.”
* Reference [source: various media news articles]
| Plaintiff | Defendant | Business Relation | Patented Technology | Courts | State | Link | ||||||
| Nichia | WOFI Leuchten | Everlight subsidiary | phosphor | Düsseldorf District Court, Germany | Nichia won the suit in the court of first instance and the court ruled for an injunction |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | REGO-Lighting | Used a white LED tube light product by Everlight subsidiary Zenar | phosphor | Düsseldorf District Court, Germany | On Dec. 5, 2016, the appeals court confirmed patent infringement and ruled in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | phosphor | Düsseldorf District Court, Germany | On Oct. 24, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Tachibana Eletech and E&E Japan | Distributor of blue LEDs manufactured by Everlight in Japan | LED chip | Tokyo District Court, Japan | On Oct. 14, 2016, the court issued an oder ruled for an infringement in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2016 |
||||||
| Nichia | Mouser | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | On Oct. 7, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | LED Package | The U.S. District Court for the Eastern District of Texas | The Federal Circuit affirmed an infringement of Nichia’s patents. |
http://www.nichia.co.jp/en/about_nichia/20
http://www.ledinside.com/news/2017/5/nic |
||||||
| Nichia | EBV Elektronik GmbH & Co. KG and EBV Management GmbH (both “EBV“) | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | Still in progress |
http://www.nichia.co.jp/en/about_nichia http://www.ledinside.com/press/2017/3/nichia _files_patent_infringement_lawsuit_against_ |
||||||
| Nichia | Everlight Electronics (China) and Beijing Ducheng Yiguang Electronic Devices Selling Center | Everlight subsidiary | phosphor | Beijing Intellectual Property Court, China | Still in progress |
http://www.nichia.co.jp/en/about_nichia |
||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | High Power LED | Düsseldorf District Court, Germany | Still in progress | |||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | Mid Power LED | Düsseldorf District Court, Germany | On April 28, 2017, Seoul filed the lawsuit. | |||||||
About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fifth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as Wicop – a simpler structured Package-Free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; Acrich, the world's leading direct AC LED; Acrich MJT multi-junction technology; a proprietary family of high-voltage LEDs; NanoDriver Series – World’s Smallest 24W DC LED Drivers and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs.
For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com
# Trademarks: Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005266/en/
Contact:
Asia
Seoul Semiconductor Co., Ltd
Jake Jung, +82 070.4391.8270
Email:
pr@seoulsemicon.com
or
Europe
Seoul
Semiconductor Europe GmbH
Ariane Heim, +49 (0)89 450 3690-0
Email:
press.eu@seoulsemicon.com
or
North
America
Seoul Semiconductor Inc.
David Cox, +1 (919) 410-9856
Email:
David.cox@seoulsemicon.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom